Catalyst Science Discovery Centre appoints director

Widnes, Cheshire-based firm welcomes Stephen Youd-Thomas

Catalyst Science Discovery Centre, an interactive science centre and museum devoted to chemistry and how the products of chemistry are used in everyday life based in Widnes, Cheshire, UK, has a new director of catalyst, which encompasses the role of ERDF project director.

Stephen Youd-Thomas runs a successful corporate and social responsibility consultancy and was formerly head of social goals at the Co-operative Group.

‘This is a wonderful opportunity to help develop the work of the UK's only science discovery centre with chemistry as its main theme. Catalyst brings chemistry alive for thousands of young people from across the North West and beyond and hopefully this experience will encourage many of them to consider a career in science in the future,’ he said.

Catalyst is an independent charitable trust operated by Catalyst Science Discovery Centre and Museum Trust.

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Manufacturing

Viatris to cut 10% of its global workforce after Indian plant fire

Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan
Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway
Manufacturing

GEA opens new technology centre in Germany

The opening of the new technology centre for pharmaceutical freeze-drying systems will strengthen the supplier's position in the growing pharmaceutical applications market
Subscribe now